Bahram Valamehr Fate Therapeutics Inc (FATE) insider trading activity

Bahram Valamehr is Chief R&D Officer of FATE THERAPEUTICS INC. Currently has a direct ownership of 358,069 shares of FATE, which is worth approximately $594,394. The most recent transaction as insider was on Jul 29, 2024, when has been sold 200,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 358K

0% 3M change

111.45% 12M change

Total Value Held $594,394

Bahram Valamehr Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 29 2024	BUY Grant, award, or other acquisition	-	200,000 Added 35.84%	358,069 Common Stock
Jan 09 2024	SELL Open market or private sale	$49,366 $4.38 p/Share	11,271 Reduced 6.66%	158,069 Common Stock
Jan 12 2023	BUY Exercise of conversion of derivative security	$579 $1.37 p/Share	423 Added 0.25%	169,340 Common Stock
Jan 10 2023	SELL Open market or private sale	$57,205 $5.24 p/Share	10,917 Reduced 6.07%	168,917 Common Stock
Jul 07 2022	SELL Open market or private sale	$518,686 $30.23 p/Share	17,158 Reduced 8.71%	179,834 Common Stock
Jul 07 2022	BUY Exercise of conversion of derivative security	$46,841 $2.73 p/Share	17,158 Added 8.01%	196,992 Common Stock
Jul 06 2022	SELL Open market or private sale	$235,809 $30.07 p/Share	7,842 Reduced 4.18%	179,834 Common Stock
Jul 06 2022	BUY Exercise of conversion of derivative security	$29,721 $3.79 p/Share	7,842 Added 4.01%	187,676 Common Stock
Mar 14 2022	SELL Open market or private sale	$809,250 $32.37 p/Share	25,000 Reduced 12.21%	179,834 Common Stock
Mar 14 2022	BUY Exercise of conversion of derivative security	$68,250 $2.73 p/Share	25,000 Added 10.88%	204,834 Common Stock
Jan 25 2022	BUY Grant, award, or other acquisition	-	33,302 Added 15.62%	179,834 Common Stock
Jan 11 2022	SELL Open market or private sale	$222,925 $48.78 p/Share	4,570 Reduced 3.02%	146,532 Common Stock
Jan 10 2022	SELL Open market or private sale	$261,613 $46.75 p/Share	5,596 Reduced 3.57%	151,102 Common Stock
Dec 13 2021	SELL Open market or private sale	$1,190,250 $47.61 p/Share	25,000 Reduced 13.76%	156,698 Common Stock
Dec 13 2021	BUY Exercise of conversion of derivative security	$68,250 $2.73 p/Share	25,000 Added 12.09%	181,698 Common Stock
Nov 19 2021	BUY Grant, award, or other acquisition	-	60,958 Added 28.01%	156,698 Common Stock
Sep 13 2021	SELL Open market or private sale	$1,668,750 $66.75 p/Share	25,000 Reduced 20.71%	95,740 Common Stock
Sep 13 2021	BUY Exercise of conversion of derivative security	$68,250 $2.73 p/Share	25,000 Added 17.15%	120,740 Common Stock
Jun 14 2021	SELL Open market or private sale	$2,246,250 $89.85 p/Share	25,000 Reduced 20.71%	95,740 Common Stock
Jun 14 2021	BUY Exercise of conversion of derivative security	$70,500 $2.82 p/Share	25,000 Added 17.15%	120,740 Common Stock
Mar 15 2021	SELL Open market or private sale	$2,319,000 $92.76 p/Share	25,000 Reduced 20.71%	95,740 Common Stock
Mar 15 2021	SELL Exercise of conversion of derivative security	$72,500 $2.9 p/Share	25,000 Reduced 17.15%	120,740 Common Stock
Jan 20 2021	BUY Grant, award, or other acquisition	-	18,013 Added 15.84%	95,740 Common Stock
Jan 11 2021	SELL Open market or private sale	$360,153 $110.68 p/Share	3,254 Reduced 4.02%	77,727 Common Stock
Jan 08 2021	SELL Open market or private sale	$724,736 $116.33 p/Share	6,230 Reduced 7.14%	80,981 Common Stock

Bahram Valamehr

Chief R&D Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells FATE shares.

Notify only if

Value

Insider Trading

Get notified when an Fate Therapeutics Inc insider buys or sells FATE shares.

Notify only if

Operation

Value

Type

News

Receive news related to FATE THERAPEUTICS INC

Track Activities on FATE

Account